拉維達韋

{{Drugbox
| Verifiedfields =
| Watchedfields =
| verifiedrevid =
| IUPAC_name = (2S)-2-{[Hydroxy(methoxy)methylidene]amino}-1-[(2S)-2-[5-(6-{2-[(2S)-1-[(2S)-2-{[hydroxy(methoxy)methylidene]amino}-3-methylbutanoyl]pyrrolidin-2-yl]-1H-1,3-benzodiazol-6-yl}naphthalen-2-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one
| image = Ravidasvir.svg
| width = 275

| tradename =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =

| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

| CAS_number_Ref =
| CAS_number = 1242087-93-9
| ATC_prefix = J05
| ATC_suffix = AP13
| PubChem = 52918888
| DrugBank_Ref =
| DrugBank =
| KEGG = D12744
| ChemSpiderID = 31141686
| ChEMBL = 3121849
| UNII_Ref =
| UNII = AL3G001BI8
| synonyms = PPI-668

| C=42 | H=50 | N=8 | O=6
| molecular_weight =
| smiles = CC(C)C@@HN1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)C@HC)NC(=O)OC)NC(=O)OC
| StdInChI = 1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1
| StdInChIKey = LCHMHYPWGWYXEL-ZYADHFCISA-N
}}

拉維達韋（INN：ravidasvir，开发代号：PPI-668）用于治疗丙型肝炎的口服药物。常与索磷布韋一起使用，治愈率为 97%。它可用于感染丙型肝炎和艾滋病的人。糖尿病患者可能發生低血糖。

拉維達韋于2021年在马来西亚和埃及取得医疗使用許可。

参考文獻